Evidence map›Paper›PMID 31836588›Full record

ArticleCold Spring Harbor molecular case studies2019

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a

Ilaria Colombo, Swati Garg, Arnavaz Danesh, Jeffrey Bruce, Patricia Shaw, Qian Tan, Rene Quevedo, Marsela Braunstein, Amit M Oza, Trevor Pugh and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ilaria Colombo *Bras Family Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario M5G 1Z5, Canada.
Swati Garg *Bras Family Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario M5G 1Z5, Canada.
Arnavaz DaneshPrincess Margaret Genomics Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
Jeffrey BrucePrincess Margaret Genomics Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
Patricia ShawAffiliate Scientist, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
Qian TanBras Family Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario M5G 1Z5, Canada.
Rene QuevedoPrincess Margaret Genomics Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
Marsela BraunsteinBras Family Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario M5G 1Z5, Canada.
Amit M OzaBras Family Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario M5G 1Z5, Canada.
Trevor PughPrincess Margaret Genomics Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
Stephanie LheureuxBras Family Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario M5G 1Z5, Canada.
University Health Network · CAUniversity of Toronto · CAPrincess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a phase III trial when compared to physician's choice chemotherapy. We report for the first time temporal changes in the tumor genome assessed in sequential tumor samples of a 48-yr-old patient with a

Indexed as

BenzimidazolesCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansMiddle AgedMutationOvarian NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)ras ProteinsReceptor, ErbB-3Signal TransductionBenzimidazolesbinimetinibERBB3 protein, humanKRAS protein, humanMYC protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)ras ProteinsReceptor, ErbB-3ovarian neoplasm

Identifiers

PMID31836588
PMCPMC6913142
OpenAlexW2998725997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.